Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
CONCLUSION: Although SGLT2 inhibitors have been reported to have adverse effects on ketoacidosis, recent studies indicate that the occurrence of ketoacidosis is relatively rare. Considering the pathological mechanism of CPI-triggered diabetes, SGLT2 inhibitors could be an effective choice if they are administered while carefully monitoring the patient's ketoacidosis.PMID:38106883 | PMC:PMC10725247 | DOI:10.3389/fpubh.2023.1264056 (Source: Cancer Control)
Source: Cancer Control - December 18, 2023 Category: Cancer & Oncology Authors: Makoto Fujiwara Masaru Shimizu Tatsuya Okano Yuko Maejima Kenju Shimomura Source Type: research
Tuberculosis reactivation demonstrated by choroiditis and inflammatory choroidal neovascular membrane in a patient treated with immune checkpoint inhibitors for malignant mucosal melanoma
ConclusionsICPIs can cause a myriad of ocular issues, both by primary immunomodulatory effects as well as secondary reactivation of latent disease. (Source: Journal of Ophthalmic Inflammation and Infection)
Source: Journal of Ophthalmic Inflammation and Infection - December 18, 2023 Category: Opthalmology Source Type: research
IgG4 ‐related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non‐small cell lung cancer: A case report
This study reports the first case of IgG4-related retroperitoneal fibrosis after the administration of chemotherapy with nivolumab and ipilimumab (NI therapy). An 80-year-old man developed lower abdominal pain eight months after NI therapy was initiated. Although the primary lesion maintained its reduced size on computed tomography, there was an increase in the soft tissue shadows intensity around the abdominal aorta, bladder, and seminal vesicles, suggesting retroperitoneal fibrosis. Blood tests showed elevated IgG4 levels. Computed tomography-guided biopsy of the retroperitoneum showed B cell-dominant lymphocyte infiltra...
Source: Thoracic Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Masashi Nishimura,
Yoshifumi Kimizuka,
Takunori Ogawa,
Motohiro Tsuchiya,
Yoshiki Kato,
Akira Matsukida,
Shunya Igarashi,
Koki Ito,
Yusuke Serizawa,
Tomomi Tanigaki,
Yuji Fujikura,
Yuka Katsurada,
Sho Ogata,
Akihiko Kawana Tags: CASE REPORT Source Type: research
Long-term Intracranial Outcomes with Combination Dual Immune-Checkpoint Blockade and SRS in Patients with Melanoma and NSCLC Brain Metastases
CONCLUSIONS: The addition of D-ICPI for patients with melanoma and NSCLC undergoing SRS is associated with improved local and intracranial control. This appears to be an effective strategy, including for patients with symptomatic or multiple BMs.PMID:38097090 | DOI:10.1016/j.ijrobp.2023.12.002 (Source: Health Physics)
Source: Health Physics - December 14, 2023 Category: Physics Authors: Eugene J Vaios Rachel F Shenker Peter G Hendrickson Zihan Wan Donna Niedzwiecki Sebastian F Winter Helen A Shih Jorg Dietrich Chunhao Wang April K S Salama Jeffrey M Clarke Karen Allen Paul Sperduto Trey Mullikin John P Kirkpatrick Scott R Floyd Zachary J Source Type: research
Long-term Intracranial Outcomes with Combination Dual Immune-Checkpoint Blockade and SRS in Patients with Melanoma and NSCLC Brain Metastases
CONCLUSIONS: The addition of D-ICPI for patients with melanoma and NSCLC undergoing SRS is associated with improved local and intracranial control. This appears to be an effective strategy, including for patients with symptomatic or multiple BMs.PMID:38097090 | DOI:10.1016/j.ijrobp.2023.12.002 (Source: Cancer Control)
Source: Cancer Control - December 14, 2023 Category: Cancer & Oncology Authors: Eugene J Vaios Rachel F Shenker Peter G Hendrickson Zihan Wan Donna Niedzwiecki Sebastian F Winter Helen A Shih Jorg Dietrich Chunhao Wang April K S Salama Jeffrey M Clarke Karen Allen Paul Sperduto Trey Mullikin John P Kirkpatrick Scott R Floyd Zachary J Source Type: research
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma
Mesothelioma is a rare and aggressive malignancy with a poor prognosis. Without treatment, the median survival time ranges between six and nine months [1]. As the diagnosis usually is made at an advanced stage most patients are not eligible for surgery and designated for palliative systemic treatment [2]. Treatment in first-line with a combination of platinum and pemetrexed resulted in a median survival benefit of three months [3]. The addition of bevacizumab resulted in an additional survival benefit of nearly three months [4]. (Source: Lung Cancer)
Source: Lung Cancer - December 13, 2023 Category: Cancer & Oncology Authors: D.W. Dumoulin, L.H. Douma, M.M. Hofman, V. van der Noort, R. Cornelissen, C.J. de Gooijer, J.A. Burgers, J.G.J.V. Aerts Source Type: research
A single ‐center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan
ConclusionsSystemic therapy and radiotherapy have improved the survival of MBM patients, but the survival of Asian patients remains poor. Our findings suggest that COMBI-ICIs are not significantly more effective than single-agent ICI or TT in treating MBM. (Source: Cancer Medicine)
Source: Cancer Medicine - December 12, 2023 Category: Cancer & Oncology Authors: Shogo Wada,
Dai Ogata,
Tairo Kashihara,
Kae Okuma,
Hirofumi Eto,
Eiji Nakano,
Akira Takahashi,
Kenjiro Namikawa,
Hiroshi Igaki,
Naoya Yamazaki Tags: RESEARCH ARTICLE Source Type: research
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events
The roles of preexisting auto-reactive antibodies in immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy are not well defined. Here, we analyzed plasma samples longitudinally collected at predefined time points and at the time of irAEs from 58 patients with immunotherapy naïve metastatic non-small cell lung cancer treated on clinical protocol with ipilimumab and nivolumab. We used a proteomic microarray system capable of assaying antibody reactivity for IgG and IgM fractions against 120 antigens for systemically evaluating the correlations between auto-reactive antibodies and certain ...
Source: Frontiers in Immunology - December 12, 2023 Category: Allergy & Immunology Source Type: research
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Eva Elleb æk, Shawez Khan, Lars Bastholt, Henrik Schmidt, Charlotte Aaquist Haslund, Marco Donia, Inge Marie Svane Source Type: research
Long-term Intracranial Outcomes with Combination Dual Immune-Checkpoint Blockade and SRS in Patients with Melanoma and NSCLC Brain Metastases
The intracranial benefit of offering dual immune-checkpoint inhibition (D-ICPI) with ipilimumab and nivolumab to patients with melanoma or non-small cell lung cancer (NSCLC) receiving stereotactic radiosurgery (SRS) for brain metastases (BMs) is unknown. We hypothesized that D-ICPI improves local control compared to SRS alone. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - December 11, 2023 Category: Radiology Authors: Eugene J. Vaios, Rachel F. Shenker, Peter G. Hendrickson, Zihan Wan, Donna Niedzwiecki, Sebastian F. Winter, Helen A. Shih, Jorg Dietrich, Chunhao Wang, April K.S. Salama, Jeffrey M. Clarke, Karen Allen, Paul Sperduto, Trey Mullikin, John P. Kirkpatrick, Tags: Clinical Investigation Source Type: research
Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases
The intracranial benefit of offering dual immune-checkpoint inhibition (D-ICPI) with ipilimumab and nivolumab to patients with melanoma or non-small cell lung cancer (NSCLC) receiving stereotactic radiosurgery (SRS) for brain metastases (BMs) is unknown. We hypothesized that D-ICPI improves local control compared with SRS alone. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - December 11, 2023 Category: Radiology Authors: Eugene J. Vaios, Rachel F. Shenker, Peter G. Hendrickson, Zihan Wan, Donna Niedzwiecki, Sebastian F. Winter, Helen A. Shih, Jorg Dietrich, Chunhao Wang, April K.S. Salama, Jeffrey M. Clarke, Karen Allen, Paul Sperduto, Trey Mullikin, John P. Kirkpatrick, Tags: Clinical Investigation Source Type: research
Cancers, Vol. 15, Pages 5787: Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy
lip
Pilar Garrido
Malignant pleural mesothelioma (MPM) is a locally aggressive disease related to asbestos exposure with a median survival for untreated patients of 4–8 months. The combination of chemotherapy based on platinum and antifolate is the standard treatment, and the addition of bevacizumab adds two months to median survival. Recently, in first-line treatment, immunotherapy combining nivolumab with ipilimumab has been shown to be superior to chemotherapy in the CheckMate-743 study in terms of overall survival (18.1 months), leading to its approval by the FDA and EMA. The positive results of thi...
Source: Cancers - December 10, 2023 Category: Cancer & Oncology Authors: Susana Cedres Augusto Valdivia Patricia Iranzo Ana Callejo Nuria Pardo Alejandro Navarro Alex Martinez-Marti Juan David Assaf-Pastrana Enriqueta Felip Pilar Garrido Tags: Review Source Type: research
Combination Therapies in Patients with Favorable Risk Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
In recent years, there have been significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) with the introduction of combination therapies involving immunotherapy (IO). Particularly, the combination of nivolumab and ipilimumab has demonstrated noteworthy improvements in overall survival (OS) when compared to sunitinib in patients classified as intermediate- and poor-risk according to the “International mRCC Database Consortium (IMDC).” These findings highlight the promising potential of IO-based combination therapies in the management of mRCC [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Hatice Bolek, Emre Yeked üz, Yüksel Ürün Tags: Systematic or Meta-analysis Studies Source Type: research
Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First Line Metastatic Uveal Melanoma: A Propensity Score Weighted Analysis
CONCLUSION: Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM. Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I. These data further support tebentafusp as the standard of care in previously untreated HLA-A*02:01+ adult patients with mUM.PMID:38048850 | DOI:10.1016/j.annonc.2023.11.013 (Source: Ann Oncol)
Source: Ann Oncol - December 4, 2023 Category: Cancer & Oncology Authors: J M Piulats C Watkins M Costa-Garc ía L Del Carpio S Piperno-Neumann P Rutkowski J C Hassel E Espinosa L de la Cruz-Merino S Ochsenreither A N Shoushtari M Orloff A K S Salama H M Goodall J-F Baurain P Nathan Source Type: research
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With < em > ATM < /em > Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
CONCLUSION: Nivolumab plus ipilimumab did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with ATM mutations.PMID:38039429 | DOI:10.1200/PO.23.00279 (Source: Cancer Control)
Source: Cancer Control - December 1, 2023 Category: Cancer & Oncology Authors: Nitin Rohatgi Michael Rothe Pam K Mangat Elizabeth Garrett-Mayer Funda Meric-Bernstam Evan Pisick Olatunji B Alese Christopher M Reynolds Ramya Thota Gina M Vaccaro Margaret von Mehren Rebecca C Arend Vi K Chiu Herbert L Duvivier Philip J Gold Keely Hack Source Type: research
